Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
Novo Nordisk A/S - share repurchase programme
08:11am, Monday, 28'th Oct 2024
Bagsværd, Denmark, 28 October 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Coun
This Is Huge News for Novo Nordisk (Hint: It Doesn't Involve Ozempic)
11:30am, Saturday, 26'th Oct 2024
Novo Nordisk just released data from a clinical trial featuring its oral semaglutide treatment, Rybelsus.
CTLT Stock Falls as Potential Hindrance to NVO Buyout Deal Increases
12:10pm, Thursday, 24'th Oct 2024
Catalent stock faces uncertainty as several pharma companies voice concern about potential limited competition following the acquisition, especially in weight-loss drug manufacturing.
Lilly to launch its obesity drug in Denmark, Novo Nordisk's home market
09:27am, Thursday, 24'th Oct 2024
Lilly will launch its Mounjaro obesity drug in Denmark next week, the U.S. drugmaker said on Thursday, bringing competition to the home country of its biggest weight-loss rival, Danish pharmaceuticals
Novo Nordisk's diabetes drug Ozempic may reduce the risk of Alzheimer's disease, study says
07:00am, Thursday, 24'th Oct 2024
Novo Nordisk's blockbuster diabetes drug Ozempic may reduce the risk of developing Alzheimer's disease, according to a new analysis of electronic health records. The findings suggest that Ozempic and
Novo Nordisk asks US to stop compounding pharmacies from making weight-loss drug copies
12:47pm, Wednesday, 23'rd Oct 2024
Novo Nordisk on Tuesday asked the U.S. Food and Drug Administration to ban compounding pharmacies from making copycat versions of its popular weight-loss and diabetes drugs, which it said were too com
Novo Nordisk's Death Cross: Is A Turnaround Coming For The Ozempic, Wegovy Maker?
12:41pm, Wednesday, 23'rd Oct 2024
Novo Nordisk A/S NVO just hit a technical red flag — a Death Cross.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
09:55am, Wednesday, 23'rd Oct 2024
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Novo Nordisk asks FDA to ban compounding pharmacies from making Ozempic, Wegovy copies
09:44am, Wednesday, 23'rd Oct 2024
Novo Nordisk asked the Food and Drug Administration to prevent compounding pharmacies from making cheaper versions of its popular weight loss injection Wegovy and diabetes treatment Ozempic. The Danis
Why Novo Nordisk (NVO) Dipped More Than Broader Market Today
06:51pm, Tuesday, 22'nd Oct 2024
Novo Nordisk (NVO) closed at $116.47 in the latest trading session, marking a -0.73% move from the prior day.
NVO's Rybelsus Meets Primary Goal in MACE Study for Diabetes Patients
12:35pm, Tuesday, 22'nd Oct 2024
A late-stage study shows that Novo Nordisk's oral semaglutide, Rybelsus, cuts the risk of MACE by 14% in T2D patients compared to placebo.
5 Large Drug Stocks Likely to Outpace Q3 Earnings Estimates
09:35am, Tuesday, 22'nd Oct 2024
Let us look at some big drug/biotech stocks, NVO, NVS, PFE, REGN and BIIB, which are poised to beat on third-quarter earnings.
Dr. Scot Gottlieb on Novo Nodrisk's oral diabetes drug, future of weight-loss drugs
09:10am, Tuesday, 22'nd Oct 2024
Former FDA Commissioner Dr. Scot Gottlieb joins 'Squawk Box' to discuss news of Novo Nordisk's oral diabetes drug cutting heart-related risks in patients, state of the weight-loss drugs market, and mo
NVO Stock Falls 5% in a Month: Should Investors Buy Now or Wait?
01:00pm, Monday, 21'st Oct 2024
Despite the current downward trend of Novo Nordisk, it is an excellent stock to buy for long-term gains, driven by the stellar performance of its GLP-1 drugs.
NVO's Alhemo Gets Positive CHMP Opinion in EU for Haemophilia A or B
12:55pm, Monday, 21'st Oct 2024
The CHMP of the regulatory body in the EU adopts a positive opinion recommending the approval of Novo Nordisk's Alhemo for haemophilia A or B with inhibitors.
